12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kyprolis carfilzomib: Phase I/II data

An open-label, French Phase I/II trial in 69 patients aged 65 years and older with newly diagnosed MM showed that IV carfilzomib plus melphalan and prednisone led to an ORR of 89%. At a median follow-up of 12 months, the estimated 2-year OS rate was 90%. The MTD was 36 mg/m 2 carfilzomib. There were 2 dose-limiting toxicities (DLTs) of fever and hypotension at the 45 mg/m 2 dose...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >